Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; An open-label, multicenter, phase 1b study Meeting Abstract
| Authors: | Roboz, G. J.; Pabst, T.; Aribi, A.; Brandwein, J. M.; Döhner, H.; Fiedler, W.; Gandini, D.; Geddes, M.; Hou, J. Z.; Howes, A. J.; Hultberg, A.; Huselton, E.; Jacobs, J.; Kane, C.; Lech-Maranda, E.; Louwers, M.; Nottage, K.; Platzbecker, U.; Rampal, R.; Salman, M.; Shah, P.; Stevens, D.; Stuart, M.; Subklewe, M.; Sumbul, A.; Wang, E. S.; Wierzbowska, A.; Yao, B.; Yee, K.; Kantarjian, H.; Borthakur, G. |
| Abstract Title: | Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; An open-label, multicenter, phase 1b study |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398801145 |
| DOI: | 10.1182/blood-2021-150371 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 369 -- Hybrid meeting, also took place online --Source: Wos |
